Malaria drug tested to shield seniors from COVID
NCT ID NCT04397328
Summary
This study aimed to see if the drug hydroxychloroquine could prevent COVID-19 in older, high-risk adults living in care facilities after they were exposed to the virus. It was designed as a Phase 3 trial but was withdrawn before any participants were enrolled. The goal was to give the drug quickly after exposure to try to stop the infection before symptoms started.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.